Qin Bao-Dong, Jiao Xiao-Dong, Yuan Ling-Yan, Liu Ke, Zang Yuan-Sheng
Department of Medical Oncology, Changzheng Hospital, Second Military Medical University, Shanghai, China.
Cancer Manag Res. 2018 Mar 7;10:439-446. doi: 10.2147/CMAR.S144850. eCollection 2018.
Adenosquamous carcinoma (ASC) of the bile duct is a rare diagnosis with poorly understood clinicopathological characteristics and disease progression, so identification of the features associated with ASC patient survival is warranted.
A population cohort study was performed using prospectively extracted data from the Surveillance, Epidemiology and End Results (SEER) database for patients with histological diagnoses of ASC of the bile duct from 1973 to 2013.
A total of 106 patients with ASC of the bile duct were included (mean age 68.1±13.5 years). Lesions from 58 patients were in the extrahepatic bile duct and 34 were located at the ampulla of Vater. Fifty-seven patients were categorized with a regional stage, 15 had localized disease, and 30 had distant disease. Most (60.4%) patients received cancer-directed surgery, and radiation was performed in 14.1% of cases. The 1-year, 2-year, and 5-year overall survival (OS) for patients with ASC of the bile duct was 30.1%, 11.3%, and 3.7%, respectively. Cancer-directed surgery offered 10 additional months of OS for patients with ASC of the bile duct and median OS was 14.0, 6.0, and 6.0 months for ampulla of Vater, extrahepatic bile duct, and intrahepatic bile duct cases, respectively. A multivariate Cox analysis showed that lesions in the ampulla of Vater (HR=0.51, 95% CI 0.26-0.99) and having surgery (HR=0.34, 95% CI 0.14-0.81) were independent protective prognostic factors for these patients.
Cancer-directed surgery and a primary lesion site of the ampulla of Vater may suggest favorable prognosis for patients with ASC of the bile duct.
胆管腺鳞癌(ASC)是一种罕见的诊断,其临床病理特征和疾病进展了解甚少,因此有必要确定与ASC患者生存相关的特征。
进行了一项人群队列研究,使用从监测、流行病学和最终结果(SEER)数据库中前瞻性提取的数据,研究对象为1973年至2013年组织学诊断为胆管ASC的患者。
共纳入106例胆管ASC患者(平均年龄68.1±13.5岁)。58例患者的病变位于肝外胆管,34例位于 Vater壶腹。57例患者被分类为区域分期,15例为局限性疾病,30例为远处疾病。大多数(60.4%)患者接受了针对癌症的手术,14.1%的病例进行了放疗。胆管ASC患者的1年、2年和5年总生存率(OS)分别为30.1%、11.3%和3.7%。针对癌症的手术使胆管ASC患者的OS延长了10个月,Vater壶腹、肝外胆管和肝内胆管病例的中位OS分别为14.0个月、6.0个月和6.0个月。多变量Cox分析显示,Vater壶腹病变(HR=0.51,95%CI 0.26-0.99)和进行手术(HR=0.34,95%CI 0.14-0.81)是这些患者独立的保护性预后因素。
针对癌症的手术和Vater壶腹的原发性病变部位可能提示胆管ASC患者预后良好。